Ocelot Bio Receives FDA Orphan Drug Designation for OCE-205
20 Dec 2023 //
BUSINESSWIRE
Ocelot Bio Appoints Lise Kjems, M.D., Ph.D., as Chief Medical Officer
18 Apr 2023 //
BUSINESSWIRE
Ocelot Bio Presents Phase 1 Data Highlighting Activity and Safety of OCE-205
04 Nov 2022 //
BUSINESSWIRE
Ocelot Bio to Present Data Highlighting Pharmacodynamic Activity
24 Oct 2022 //
BUSINESSWIRE
Ocelot Bio Receives FDA ODD for OCE-205 for Hepatorenal Syndrome
22 Aug 2022 //
BUSINESSWIRE